Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

0.4471 +0.0071 (+1.61%)
Streaming Delayed Price Updated: 11:45 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 722,546
Open 0.4500
Bid (Size) 0.4456 (4)
Ask (Size) 0.4482 (4)
Prev. Close 0.4400
Today's Range 0.4352 - 0.4643
52wk Range 0.3500 - 2.030
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME
From Kahn Swick & Foti, LLC
Via Business Wire
3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts
Hercules Capital, Pfizer and Target offer stability, growth potential and reliable dividends in the realm of high-dividend stocks. 
Via InvestorPlace

Performance

YTD
-50.78%
-50.78%
1 Month
+5.57%
+5.57%
3 Month
-2.89%
-2.89%
6 Month
-38.11%
-38.11%
1 Year
-77.19%
-77.19%

More News

Read More
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
From 23andMe, Inc.
Via GlobeNewswire
3 Ultra-High-Yield Dividend Stocks to Buy Hand Over Fist Right This Instant
Via The Motley Fool
Looking Into 23andMe Holding's Recent Short Interest
Via Benzinga
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Via InvestorPlace
23andMe Launches New Genetic Report on Bipolar Disorder
From 23andMe, Inc.
Via GlobeNewswire
Why 23andMe Stock Tumbled 10% on Tuesday
Via The Motley Fool
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
From 23andMe, Inc.
Via GlobeNewswire
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
From 23andMe, Inc.
Via GlobeNewswire
ME Stock Earnings: 23andMe Holding Beats EPS, Beats Revenue for Q4 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q4 and Full Year FY2024 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case
From Potter Handy LLP
Via Business Wire
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From 23andMe, Inc.
Via GlobeNewswire
This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next
Via The Motley Fool
Nasdaq Down 0.5%; Lithium Americas Shares Slide
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future
Via Benzinga
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Is Lithium Americas (LAC) Stock Down 28% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.